10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2009 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Net Sales | $ 30,764,707 | 29,527,552 | 25,914,238 |
| Cost of products sold | 13,209,329 | 12,612,022 | 11,422,046 |
| Research and development | 2,743,733 | 2,688,811 | 2,505,649 |
| Acquired in-process research and development | 170,000 | 97,256 | |
| Selling, general and administrative | 8,405,904 | 8,435,624 | 7,407,998 |
| Total Operating Cost and Expenses | 24,528,966 | 23,833,713 | 21,335,693 |
| Operating Earnings | 6,235,741 | 5,693,839 | 4,578,545 |
| Interest expense | 519,656 | 528,474 | 593,142 |
| Interest (income) | (137,779) | (201,229) | (136,752) |
| (Income) from the TAP Pharmaceutical Products Inc. joint venture | (118,997) | (498,016) | |
| Net foreign exchange (gain) loss | 35,584 | 84,244 | 14,997 |
| Other (income) expense, net | (1,375,494) | (454,939) | 135,526 |
| Earnings from Continuing Operations Before Taxes | 7,193,774 | 5,856,286 | 4,469,648 |
| Taxes on Earnings from Continuing Operations | 1,447,936 | 1,122,070 | 863,334 |
| Earnings from Continuing Operations | 5,745,838 | 4,734,216 | 3,606,314 |
| Gain on Sale of Discontinued Operations, net of taxes | 146,503 | ||
| Net Earnings | 5,745,838 | 4,880,719 | 3,606,314 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.71 | 3.06 | 2.34 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.10 | ||
| Net Earnings (in dollars per share) | 3.71 | 3.16 | 2.34 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.69 | 3.03 | 2.31 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.09 | ||
| Net Earnings (in dollars per share) | 3.69 | 3.12 | 2.31 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,546,983 | 1,545,355 | 1,543,082 |
| Dilutive Common Stock Options and Awards (in shares) | 8,143 | 15,398 | 16,975 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,555,126 | 1,560,753 | 1,560,057 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 66,189 | 30,579 | 6,406 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2009 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Cash Flow From (Used in) Operating Activities of Continuing Operations: | |||
| Net earnings | $ 5,745,838 | 4,880,719 | 3,606,314 |
| Less: Gain on sale of discontinued operations | 146,503 | ||
| Earnings from continuing operations | 5,745,838 | 4,734,216 | 3,606,314 |
| Adjustments to reconcile earnings from continuing operations to net cash from operating activities of continuing operations - | |||
| Depreciation | 1,210,977 | 1,051,728 | 1,072,855 |
| Amortization of intangible assets | 878,533 | 787,101 | 782,031 |
| Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture | (797,130) | ||
| Share-based compensation | 366,357 | 347,015 | 429,677 |
| Gain on dissolution of the TAP Pharmaceutical Products Inc. joint venture | (94,248) | ||
| Acquired in-process research and development | 170,000 | 97,256 | |
| Investing and financing (gains) losses, net | 41,967 | 111,238 | 356,331 |
| Trade receivables | (387,749) | (948,314) | (431,846) |
| Inventories | 230,555 | (257,476) | 131,324 |
| Prepaid expenses and other assets | (386,889) | 436,218 | (418,344) |
| Trade accounts payable and other liabilities | (374,715) | 569,056 | (82,960) |
| Income taxes | 577,416 | 160,830 | (261,539) |
| Net Cash From Operating Activities of Continuing Operations | 7,275,160 | 6,994,620 | 5,183,843 |
| Cash Flow From (Used in) Investing Activities of Continuing Operations: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (2,370,630) | (250,000) | |
| Acquisitions of property and equipment | (1,089,048) | (1,287,724) | (1,656,207) |
| Sales of Boston Scientific common stock | 318,645 | 568,437 | |
| Purchases of investment securities | (248,970) | (923,937) | (32,852) |
| Proceeds from sales of investment securities | 16,306 | 130,586 | 17,830 |
| Other | (6,368) | (75,061) | (33,485) |
| Net Cash (Used in) Investing Activities of Continuing Operations | (3,698,710) | (2,087,491) | (1,136,277) |
| Cash Flow From (Used in) Financing Activities of Continuing Operations: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 3,217,331 | (324,739) | (3,603,481) |
| Proceeds from issuance of long-term debt | 3,000,000 | 3,500,000 | |
| Repayments of long-term debt | (2,483,176) | (913,948) | (441,012) |
| Purchases of common shares | (826,345) | (1,081,806) | (1,058,793) |
| Proceeds from stock options exercised, including income tax benefit | 508,669 | 1,008,843 | 1,249,804 |
| Dividends paid | (2,414,460) | (2,174,252) | (1,959,150) |
| Net Cash From (Used in) Financing Activities of Continuing Operations | 1,002,019 | (3,485,902) | (2,312,632) |
| Effect of exchange rate changes on cash and cash equivalents | 118,848 | (115,160) | 200,258 |
| Net cash provided from the sale of discontinued operations | 349,571 | ||
| Net Increase in Cash and Cash Equivalents | 4,697,317 | 1,655,638 | 1,935,192 |
| Cash and Cash Equivalents, Beginning of Year | 4,112,022 | 2,456,384 | |
| Cash and Cash Equivalents, End of Year | 8,809,339 | 4,112,022 | 2,456,384 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2009 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2009 | Dec 31, 2008 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 8,809,339 | 4,112,022 |
| Investments, including $307,500 of investments measured at fair value at December 31, 2007 | 1,122,709 | 967,603 |
| Trade receivables, less allowances of - 2009: $311,546; 2008: $263,632; 2007: $258,288 | 6,541,941 | 5,465,660 |
| Inventories: | ||
| Finished products | 2,289,280 | 1,545,950 |
| Work in process | 448,487 | 698,140 |
| Materials | 527,110 | 531,759 |
| Total inventories | 3,264,877 | 2,775,849 |
| Deferred income taxes | 2,364,142 | 2,462,871 |
| Other prepaid expenses and receivables | 1,210,883 | 1,258,554 |
| Total Current Assets | 23,313,891 | 17,042,559 |
| Investments | 1,132,866 | 1,073,736 |
| Property and Equipment, at Cost: | ||
| Land | 546,204 | 509,606 |
| Buildings | 4,010,439 | 3,698,861 |
| Equipment | 11,325,450 | 10,366,267 |
| Construction in progress | 604,813 | 613,939 |
| Property and Equipment, at Cost, gross | 16,486,906 | 15,188,673 |
| Less: accumulated depreciation and amortization | 8,867,417 | 7,969,507 |
| Net Property and Equipment | 7,619,489 | 7,219,166 |
| Intangible Assets, net of amortization | 6,291,989 | 5,151,106 |
| Goodwill | 13,200,174 | 9,987,361 |
| Deferred Income Taxes and Other Assets | 858,214 | 1,945,276 |
| Total Assets | 52,416,623 | 42,419,204 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 4,978,438 | 1,691,069 |
| Trade accounts payable | 1,280,542 | 1,351,436 |
| Salaries, wages and commissions | 1,117,410 | 1,011,312 |
| Other accrued liabilities | 4,363,032 | 4,216,742 |
| Dividends payable | 620,640 | 559,064 |
| Income taxes payable | 442,140 | 805,397 |
| Obligation in connection with conclusion of the TAP Pharmaceutical Products Inc. joint venture | 36,105 | 915,982 |
| Current portion of long-term debt | 211,182 | 1,040,906 |
| Total Current Liabilities | 13,049,489 | 11,591,908 |
| Long-term Debt | 11,266,294 | 8,713,327 |
| Post-employment Obligations and Other Long-term Liabilities | 5,202,111 | 4,595,278 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | 0 | 0 |
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2009: 1,612,683,987; 2008: 1,601,580,899; 2007: 1,580,854,677 | 8,257,873 | 7,444,411 |
| Common shares held in treasury, at cost - Shares: 2009: 61,516,398; 2008: 49,147,968; 2007: 30,944,537 | (3,310,347) | (2,626,404) |
| Earnings employed in the business | 17,054,027 | 13,825,383 |
| Accumulated other comprehensive income (loss) | 854,074 | (1,163,839) |
| Total Abbott Shareholders' Investment | 22,855,627 | 17,479,551 |
| Noncontrolling Interests in Subsidiaries | 43,102 | 39,140 |
| Total Shareholders' Investment | 22,898,729 | 17,518,691 |
| Total Liabilities and Shareholders' Investment | 52,416,623 | 42,419,204 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |